Opus Medical Therapies is a medical device company that is developing a transcatheter tricuspid valve replacement device. The device is designed to fully replace the malfunctioning tricuspid valve, whereas most current treatments simply aim to repair it. Beginning with extensive clinical experience in valve therapies, the Opus Medical founders have achieved significant milestones already as they pursue an accelerated route to Revenue.
Venus Medtech (Hangzhou) Inc, the leading Chinese transcatheter heart valve company and Opus have recently announced a partnership agreement to develop, manufacture and sell these TMVR and TTVR products in Greater China. This agreement, covering the whole Greater China market, will allow physicians and patients in this region to benefit from transcatheter mitral and tricuspid valve replacement. The combination is unavailable in any other market or from any other company. Tidewater participated in the seed round for Opus in 2018. Co-investors included current and former executives of Boston Scientific and Medtronic.
Member count: 11-50
Founded date: 2017
Investors 1
| Date | Name | Website |
| - | Tidewater ... | tidewateri... |